StemCell Therapy

Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones.

Timing the Immune Response of COVID-19

A study from the Keck School of Medicine at USC suggests that temporarily suppressing the immune system during the early stages of COVID-19 can avoid severe symptoms. This is related to research showing an interaction between the bodys two primary lines of defense may be overstimulating the patients immune system. The research was published in the Journal of Medical Virology.

Some COVID-19 patients may experience a resurgence of the disease after an apparent easing of symptoms, said Sean Du, adjunct researcher and lead author of the study. Its possible that the combined effect of the adaptive and the innate immune responses may reduce the virus to a low level temporarily. However, if the virus is not completely cleared, and the target cells regenerate, the virus can take hold again and reach another peak.

As a result of what they call a counterintuitive idea, they are proposing a short regimen of an appropriate immunosuppressant drug applied early in the disease. Du said, With the right suppressive agent, we may be able to delay the adaptive immune response and prevent it from interfering with the innate immune response, which enables faster elimination of the virus and the infected cells.

The bodys innate immune response begins right after infection. The second line of defense is the adaptive immune response, which doesnt start for several days if any virus remains. It uses what it has learned about the virus to marshal a variety of T-cells and B-cells to attack the remaining virus. COVID-19, which targets surface cells throughout the respiratory system, has an average incubation of six days and a slower disease progression than, for example, the flu. The adaptive immune response, they believe, may start before the target cells are depleted, which slows down the infection and interferes with the innate immune responses ability to kill off most of the virus.

High Blood Pressure Medications Safe for COVID-19 Patients

One of the clear comorbidities for COVID-19 is high blood pressure. NYU Langone Health/NYU School of Medicine studied 12,594 patients to determine if common high blood pressure drugs increased the risk of contracting the disease or of developing severe disease. The study found no links between treatment with four drug classes: angiotensin-converting enzyme (ACE) inhibitors; angiotensin receptor blockers (ARBs); beta blockers; or calcium channel blockers. They also did not find an increased likelihood of a positive test for COVID-19 in people taking these medications.

Researchers ID Protein Linked to Lyme Disease Arthritis

Investigators at Washington State University identified a surface protein called VIsE that prevents the immune system from fighting Lyme disease. In particular, the study looked at how VIsE protects one of the primary proteins response for persistent arthritis in the disease. This is one step closer to being able to develop a vaccine against Lyme.

Korean Researchers ID 2 Already Approved Drugs that Show Promise Against COVID-19

Korean investigators screened 48 FDA-approved drugs against SARS-CoV-2 and identified two that showed promise. One is niclosamide, marketed by Bayer under the name Niclocide, as well as by others, and is used to treat tapeworm infections. The drug generally has slow absorption, which would likely diminish its effectiveness for COVID-19. The second is ciclesonide, an inhaled corticosteroid used to treat asthma and allergic rhinitis.

Activating an Estrogen Receptor Shows Promise for Halting Pancreatic Cancer

Scientists at the University of Pennsylvania School of Medicine found that activating the G protein-coupled estrogen receptor (GPER), found on the surface of many normal and cancer tissues, appears to stop pancreatic cancer from growing. It also appears to make the cancer cells more visible to the immune system, meaning it should improve immunotherapy. It has generally been noted that women have better outcomes than men for most cancer types. But, the concept that cancers in non-reproductive tissues may also be influenced by sex steroid hormones is a fairly recent concept.

Key Insight into Prion Diseases

An infectious prion is a protein without nucleic acid, linked to mad cow disease and similar disease in humans, Creutzfeldt-Jakob disease, as well as fatal familial insomnia and kuru. These diseases are always fatal and very poorly understood how prions actually cause disease. Tricia Serio, dean of the College of Natural Sciences and professor of biochemistry and molecular biology at University of Massachusetts Amherst, identified a key piece of the puzzle. It has been known that prion protein (PrP) misfolding is part of the disease process. In mammals, the protein quality control system responds to folding mistakes with chaperone molecules that search for misfolds and attempt to correct the mistakes. Prions misfold so fat chaperones cant keep up. The new finding was that prion aggregates come in different sizesfor the same proteinand it turns out that the seed complex has to double in size for the disease to persist. The minimum size of the prion determines whether the chaperone can win.

Genetic Complexity and Redundancy Complicates Precision Medicine

Precision medicine is the concept that each persons genetic makeup uniquely affects their response to drugs. Mapping of the human genome, completed in 2003, opened up the field. Researchers with McMaster University, noting that precision and personalized medicine hasnt quite lived up to its promise, undertook a massive review of decades of research in the field, which they published in Genomic Medicine.

Their review found that unnecessary complexity in evolutionary pathways need to be further understood, right down to the level of genomic variations between individual cells in the same person, before personalized medicine can be leveraged effectively.

Our bodies have an immense ability to change and to cope with issues that arise, said Bhagwati Gupta, who conducted the research with fellow evolutionary biologist Rama Singh. Context matters in our genome. Even a simple mutation can have a profound effect on the body, when acting in combination with others.

The authors note that individual genes dont determine sickness or health on their own. They interact with groups of other genes and the environment in ways that are only starting to be understood.

The idea has long been that individual genetic mutations could be classified as good, bad or neutral, Singh says. Genes, though, do not work alone, and so no single gene can be considered to be good, bad or neutral in all contexts.

Read the original post:
Research Roundup: Timing the Immune Response of COVID-19 and More - BioSpace

A medical worker walks in front of Transform MD Medical Center in White Plains, N.Y., where antibody testing was being offered. Pablo Monsalve/VIEW press/Corbis via Getty Images hide caption

A medical worker walks in front of Transform MD Medical Center in White Plains, N.Y., where antibody testing was being offered.

Most people infected with the novel coronavirus develop antibodies in response.

But scientists don't know whether people who have been exposed to the coronavirus will be immune for life, as is usually the case for the measles, or if the disease will return again and again, like the common cold.

"This to me is one of the big unanswered questions that we have," says Jeffrey Shaman, a professor of environmental health sciences at Columbia University, "because it really says, 'What is the full exit strategy to this and how long are we going to be contending with it?' "

He's one of many scientists on a quest for answers. And the pieces are starting to fall into place.

Antibodies, which are proteins found in the blood as part of the body's immune response to infection, are a sign that people could be developing immunity. But antibodies are by no means a guarantee a person will be protected for life or even for a year.

Shaman has been studying four coronaviruses that cause the common cold. "They're very common and so people seem to get them quite often," Shaman says. Ninety percent of people develop antibodies to those viruses, at least in passing, but "our evidence is those antibodies are not conferring protection."

That may be simply because colds are relatively mild, so the immune system doesn't mount a full-blown response, suggests Stanley Perlman, a pediatrician who studies immunology and microbiology at the University of Iowa. "That's why people get colds over and over again," he says. "It doesn't really tickle the immune response that much."

He's studied one of the most severe coronaviruses, the one that causes SARS, and he's found that the degree of immunity depended on the severity of the disease. Sicker people remained immune for much longer, in some cases many years.

For most people exposed to the novel coronavirus, "I think in the short term you're going to get some protection," Perlman says. "It's really the time of the protection that matters."

Perlman notes that for some people the symptoms of COVID-19 are no worse than a cold, while for others they are severe. "That's why it's tricky," he says, to predict the breadth of an immune response.

And it's risky to assume that experiences with other coronaviruses are directly applicable to the new one.

"Unfortunately, we cannot really generalize what kind of immunity is needed to get protection against a virus unless we really learn more about the virus," says Akiko Iwasaki, a Howard Hughes Medical Institute investigator at the Yale University School of Medicine.

An immunobiologist, she is part of a rapidly expanding effort to figure this out. She and her colleagues are already studying the immune response in more than 100 patients in the medical school hospital. She's encouraged that most people who recover from the coronavirus have developed antibodies that neutralize the coronavirus in a petri dish.

"Whether that's happening inside the body we don't really know," she cautions.

Research like hers will answer that question, eventually.

But not all antibodies are protective. Iwasaki says some can actually contribute to the disease process and make the illness worse. These antibodies can contribute to inflammation and lead the body to overreact. That overreaction can even be deadly.

"Which types of antibodies protect the host versus those that enhance the disease? We really need to figure that out," she says.

The studies at Yale will follow patients for at least a year, to find out how slowly or quickly immunity might fade. "I wish there was a shortcut," Iwasaki says, "but we may not need to wait a year to understand what type of antibodies are protective."

That's because she and other immunologists are looking for patterns in the immune response that will identify people who have long-term immunity.

Researchers long ago figured out what biological features in the blood (called biomarkers) correlate with immunity to other diseases, says Kari Nadeau, a pediatrician and immunologist at the Stanford University School of Medicine. She expects researchers will be able to do the same for the new coronavirus.

Nadeau is working on several studies, including one that seeks to recruit 1,000 people who were previously exposed to the coronavirus. One goal is to identify people who produce especially strong, protective antibody responses. She says the antibody-producing cells from those people can potentially be turned into vaccines.

Another critical question she's zeroing in on is whether people who become immune are still capable of spreading the virus.

"Because you might be immune, you might have protected yourself against the virus," she says, "but it still might be in your body and you're giving it to others."

It would have huge public health implications if it turns out people can still spread the disease after they've recovered. Studies from China and South Korea seemed to suggest this was possible, though further studies have cast doubt on that as a significant feature of the disease.

Nadeau is also trying to figure out what can be said about the antibody blood-tests that are now starting to flood the market. There are two issues with these tests. First, a positive test may be a false-positive result, so it may be necessary to run a confirmatory test to get a credible answer. Second, it's not clear that a true positive test result really indicates a person is immune and, if so, for how long.

Companies would like to be able to use these tests to identify people who can return to work without fear of spreading the coronavirus.

"I see a lot of business people wanting to do the best for their employees, and for good reason," Nadeau says. "And we can never say you're fully protected until we get enough [information]. But right now we're working hard to get the numbers we need to be able to see what constitutes protection and what does not."

It could be a matter of life or death to get this right. Answers to these questions are likely to come with the accumulation of information from many different labs. Fortunately, scientists around the world are working simultaneously to find answers.

You can contact NPR Science Correspondent Richard Harris at rharris@npr.org.

Originally posted here:
Do Antibodies Against The Novel Coronavirus Prevent Reinfection? : Shots - Health News - NPR

Herpes simplex viruss VP1-2 protein can deactivate the early immune response.

Herpes simplex virus (HSV1) infections are initiated at mucosal surfaces where the virus infects epithelial cells. When HSV1 spreads from the peripheral nerves and into the central nervous system, it can infect the brain and cause herpes simplex encephalitis, a rare disease with high mortality if left untreated. In most cases, the innate immune system prevents HSV1 brain infection, but HSV1 is sometimes able to evade the brains defenses. A research team from Aarhus University, University of Oxford, and University of Gothenburg, led by first author Chiranjeevi Bodda in Sren Paludans lab, discovered a molecular mechanism that helps HSV1 infect the brain, which they present in a study that will be published today (May 8, 2020) in the Journal of Experimental Medicine (JEM).

The stimulator of interferon genes (STING) protein plays an important role in immunity, and it is activated by a viruss DNA during viral infection. STING initiates a cascade of cellular actions that help fight the invader. Those initial efforts include gene activation and production of cytokine proteins such as type I interferon (IFN) that boost the immune response. HSV1 has evolved multiple mechanisms to evade the host cells induction of type I IFN, Bodda explains, but how HSV1 evades the type I IFN response in the brain were not well understood.

Herpes simplex virus (HSV1) replication in brain slices was strongly impaired in the absence of its VP1-2 proteins de-ubiquitination activity (DUB, bottom row), as shown here by the reduced number of virus-producing cells (black). This highlights VP1-2s role in suppressing immunity. Credit: Bodda et al. 2020

The research team worked to identify proteins encoded in HSV1s genome that promoted HSV1s immune evasion in the brain. They infected mouse brain cells grown in culture with HSV1 mutants that were missing key genes, or whose gene activity was altered, and found that a HSV1 containing a mutated VP1-2 gene showed increased innate immune responses. Mice showed a similarly robust immune response against HSV1 with mutant VP1-2. This indicated that normal VP1-2 suppresses immunity.

The key difference between normal VP1-2 and the mutant VP1-2 was the mutant lacked its ability to remove a post-translational modification, called ubiquitin, from other proteins inside host cells after it infects them. Ubiquitin is one of several post-translational modifications known to modulate the STING cascades immune response. The team found that VP1-2 was targeting the STING activity in brain immune cells, known as microglia. The team further showed that VP1-2 can directly remove STING ubiquitination, which prevented STING from being activated for signaling. Before this study there was no knowledge on viruses altering ubiquitin in the brains immune response, Paludan says.

Our study shows that HSV1 targets STING ubiquitination in the brain to promote viral infection and potentially progression to herpes simplex encephalitis, Bodda says. A drug that inhibits the viruss ability to remove ubiquitin could allow brain cells to mount an efficient antiviral response against HSV1. This could especially benefit immunocompromised patients with severe HSV1 brain infection, particularly in cases that are resistant to the standard acyclovir treatment.

Paludan adds that though the study focuses on herpesviruses, there are parallels to the coronavirus and relevance to the COVID-19 pandemic. Our results lead us to hope that if we can prevent viruses from blocking STING, then we can prevent the virus from replicating. That could pave the way for new principles for treatment of herpes, influenza and also the coronavirus.

Rference: HSV1 VP1-2 deubiquitinates STING to block type I interferon expression and promote brain infection by Chiranjeevi Bodda, Line Reinert, Stefanie Fruhwrth, Timmy Richardo, Chenglong Sun, Bao-cun Zhang, Maria Kalamvoki, Anja Pohlmann, Trine Mogensen, Petra Bergstrm, Lotta Agholme, Peter OHare, Beate Sodeik, Mads Gyrd-Hansen, Henrik Zetterberg and Soren Paludan, 8 May 2020, Journal of Experimental Medicine (JEM).DOI: 10.1084/jem.20191422

See the article here:
Herpes Simplex Virus Can Infect the Brain by Evading the Immune Response - SciTechDaily

The innate immune system is full of targets that could be harnessed against diseases from cancer to lupus to epilepsy. But researchers have struggled to hit them because they didnt know the structure of those targets.

We didnt know the confirmation [of the targets], where the pockets are, how big they are, Marcelo Bigal, CEO of Ventus Therapeutics, told FierceBiotech. Which means trying to develop a drug against something you dont seeits drug development with the lights off.

With its structural immunology technology, Ventus is switching the lights on, emerging from stealth with $60 million from Versant Ventures and GV to advance three programs. The company is developing multiple small molecules against each of the three targets but is keeping specific disease areas under wraps, Bigal said.

Maintaining Momentum: Applying Recent Regulatory Guidance in the Midst of the Coronavirus

A panel of CATO SMS experts will review the key issues contained in the emerging Agency Guidance and offer thoughts on what changes and options for sponsors may be seen in the coming months.

RELATED: Quench Bio emerges with $50M to treat severe inflammatory diseases

The company is working to inhibit the targets, which could be useful in several areas including brain, immune and cardiometabolic disorders as well as monogenic diseases, in which a genetic mutation causes the body to make too much of a disease-causing protein. But its also looking to stimulate those targets, which could come in handy fighting cancer.

Ventus pipeline aims at two main pathways of the innate immune system: the inflammasome and the DNA-sensing pathway, also called the interferon pathway. They form the bodys first line of defense, sensing danger within cells and sacrificing those cells to contain the threat, Bigal said. The companys platform does more than elucidate protein structureit also surmounts problems scientists have faced when trying to drug the targets in a lab dish.

RELATED: IFM gets new CEO, bags another $55M to launch incubator, new subsidiaries

The targets exist as monomers, or small pieces of proteins, inside cells until they sense a threat. In response, theyll assemble into a larger protein, Bigal said.

But when you put monomers in vitro to do drug development, they immediately oligomerize and become this very large chunk of protein that nobody can handle, he said. With Ventus technology, its scientists can purify and immobilize these proteins, so they can study drugs in vitro before moving on to animal studies, where in the past, they would have gone straight to animal studies in a trial-and-error approach.

Ventus three programs are fully funded through meaningful inflection points, but Ventus has nine other targets that its not actively working on, Bigal said. All 12 offer partnership opportunities, whether a partner is interested in pursuing its three selected targets in other disease areas or in a target-based, disease area-based or platform-wide partnership.

Because we are well-funded, that means in the next month, its pipeline, pipeline, pipeline But meanwhile, we are allowing ourselves to have very selective conversations with pharma to foster possibilities for a quality partnership, Bigal said.

The company, which is based in Boston and Montreal, plans to grow to more than 30 scientists this year.

Follow this link:
Ventus uncloaks with $60M to chase targets in the innate immune system - FierceBiotech

Could suppressing the body's natural immune system help COVID-19 patients with severe symptoms recover from the illness? Scientists in America have suggested that it might, and are carrying out trials to test the method. Our immune system is essential in protecting us from the germs and bacteria we encounter every day, but doctors have observed that some of the fatalities caused by COVID-19 are brought about by the immune system going into overdrive and attacking healthy cells, a process known as a cytokine storm. Cytokine storms have been recorded as a complication of respiratory diseases such as SARS and MERS, and are thought to have been linked to the high fatality rate of the H5N1 influenza virus, also known as bird flu. It has also been observed in standard influenza cases. However, after running models comparing COVID-19 to the flu, researchers at the University of Southern California found that the progression of the new coronavirus was slower, In a paper published by the Journal of Medical Virology, the researchers suggested that the slower rate may be potentially increasing the pathogenic immune response in COVID-19 patients, the South China Morning Post (SCMP) has reported. The human immune system has two methods of fighting invasive pathogens: innate and adaptive. The innate, non-specific response is the first to kick in, quickly moving to attack foreign cells in the body as soon as they are detected. The adaptive response, which is specific to the pathogen, starts days later if the pathogen is still detected within the body. According to the research paper, the flu has an incubation period of only 48 hours or less, during which time the virus attacks cells on the surface of the upper respiratory system, killing almost all of them within that time period. But after that, the virus has nothing to attack, leaving the way clear for the innate immune response to attack the virus in turn, clearing it from the body before the adaptive response kicks in. With COVID-19, the virus takes longer to take hold - about six days. The researchers suggest that this gives the adaptive immune response time to activate, which can interfere with the innate response. The danger is, as the infection keeps going on, it will mobilize the whole of the adaptive immune response with its multiple layers, said Weiming Yuan, an associate professor from the University of Southern California and co-author of the paper, according to SCMP. This longer duration of viral activity may lead to an overreaction of the immune system, called a cytokine storm, which kills healthy cells, causing tissue damage.It may also explain why some people experience a second, more severe wave of the virus after an initial recovery period. Its possible that the combined effect of the adaptive and the innate immune responses may reduce the virus to a low level temporarily. However, if the virus is not completely cleared, and the target cells regenerate, the virus can take hold again and reach another peak, he said.The researchers have suggested that suppressing the immune system within this response window could delay the adaptive immune response, giving the innate system time to clear the virus from the patient's system before the immune system goes into overload. Based on the results of the mathematical modelling, we proposed a counterintuitive idea that a short regimen of a proper immunosuppressant drug applied early in the disease process may improve a patients outcome, said Sean Du, a researcher from the University of Southern California and co-author of the paper, according to SCMP. With the right suppressive agent, we may be able to delay the adaptive immune response and prevent it from interfering with the innate immune response, which enables faster elimination of the virus and the infected cells.However, not all medical professionals are in agreement with the researchers' suggestion. Ashley St. John, an immunologist at Duke University and National University of Singapore Medical School said that the proposed treatment was potentially very risky, and that a more targeted approach would be better. Suppressing the adaptive immune system is a very drastic step. It can be very dangerous because youre crippling your bodys ability to clear that last bit of infection, she said. Itd be nice if we can find something more specific, that is causing the pathology, which tipped the balance into severe disease rather than targeting the whole adaptive immune system.Du pointed out that at this stage the idea was only a theory which would need experimental research to back it up, he suggested animal trials would be a good way to do that. But, he added, any drug used to suppress the system would only be active for a short time, allowing the immune system to come back in afterwards and finish the job.

Follow this link:
Suppressing immune system could provide counterintuitive COVID-19 therapy - The Jerusalem Post

Changhong Zhao,1 Xuebin Song,1 Xiaoyuan Lu2

1School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, Henan, 453003, Peoples Republic of China; 2College of Medical Engineering, Xinxiang Medical University, Henan 453003, Peoples Republic of China

Correspondence: Changhong Zhao Tel/Fax +86 373 3029444Email 15921061530@163.com

Introduction: Cells exhibit high sensitivity and a diverse response to the nanotopography of the extracellular matrix, thereby endowing materials with instructive performances formerly reserved for growth factors. This finding leads to opportunities for improvement. However, the interplay between the topographical surface and cell behaviors remains incompletely understood.Methods: In the present study, we showed nanosurfaces with various dimensions of nanopits (200 750 nm) fabricated by self-assembling polystyrene (PS) nanospheres. Human adipose-derived stem cell behaviors, such as cell morphology, adhesion, cytoskeleton contractility, proliferation, and differentiation, were investigated on the prepared PS nanopit surface.Results: The osteogenic differentiation can be enhanced by nanopits with a diameter of 300 400 nm.Discussion: The present study provided exciting new avenues to investigate cellular responses to well-defined nanoscale topographic features, which could further guide bone tissue engineering and stem cell clinical research. The capability to control developing biomaterials mimicking nanotopographic surfaces promoted functional tissue engineering, such as artificial joint replacement, bone repair, and dental applications.

Keywords: osteo-differentiation, nanotopography, polystyrene

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Here is the original post:
Directional Osteo-Differentiation Effect of hADSCs on Nanotopographica | IJN - Dove Medical Press

Includes EUR 4.75 million bridge loan announced 29 April now fully granted

Gosselies, Belgium, 7May 2020 BONE THERAPEUTICS(Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it has received EUR 4.0 million as a result of issuing, to existing investors, subordinated bonds with the option to convert. This enables Bone Therapeutics bond investors to be repaid in the companys shares, with a conversion price of EUR 7.0 per share. This additional EUR 4.0 million financing has been achieved a week after the EUR 11.0 million financing round.

In addition, Bone Therapeutics confirms the granting of EUR 4.75 million bridge loans provided by commercial banks, detailed in theEUR 11.0 million financing release from April 29, 2020. This follows Sowalfin receiving regulatory approval of the credit assurance that cover the bridge loans. The total amount of committed gross proceeds for both funding operations now amount to EUR 15.0 million. This will further extend Bone Therapeutics runway into Q2 2021.

Bone Therapeutics has achieved this additional financing in the current financial climate as a result of the confidence of our investors both in Bone Therapeutics as a company, as well as the unique potential of our innovative product portfolio. This total recent financing will enable us to execute our clinical development strategy and to advance our promising product candidates towards commercialization and closer to patients, said Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics. The combination of todays financing, as well as that secured last week by Bone Therapeutics, now totals over EUR 15 million. This allows us to continue operations on this basis alone into the second quarter of 2021. This blend additionally combines a range of financing that is more suited to Bone Therapeutics than the dilution of a traditional share issuance.

The unsecured convertible bonds will be issued in registered form, redeemable at 100 percent of their principal amount with a maturity of 36 months and a coupon of 8 percent per annum. The coupon will be payable annually. The conversion price of EUR 7.0 per share mitigates the dilution of existing shareholders in the event that the bonds would be redeemed in ordinary shares of Bone Therapeutics. The specific terms of the CBs can be found in theInvestor sectionof Bone Therapeutics website.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and bone diseases. The Company has a broad, diversified portfolio of bone cell therapies and an innovative biological product in later-stage clinical development, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is entering Phase III development for the treatment of pain in knee osteoarthritis. Positive Phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement. The clinical trial application (CTA) for the pivotal Phase III program has been approved by the relevant authorities allowing the start of the study.

Bone Therapeutics other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, scalable cutting-edge manufacturing process. Following the CTA approval by the Belgian regulatory authority, the Company is ready to start the Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process.

The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy and maxillofacial and dental applications.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at http://www.bonetherapeutics.com.

See the rest here:
Bone Therapeutics raises additional EUR 4.0 million, totalling EUR 15 million, providing runway into Q2 2021 - PharmiWeb.com

As the rumblings of a pandemic began to be felt at the beginning of the year, scientists at Penn started work to develop a vaccine and assess possible treatments. But the scope of COVID-19 studies at the University goes much broader. Scientists whose typical work finds them investigating autoimmune disease, influenza, HIV/AIDS, Ebola, cancer, hemophilia, and more, are now applying their deep understanding of biology to confront a novel threat.

The more scientists and clinicians observe about the virus, the more avenues of investigation emerge, aiming to shed light on questions such as what happens once the virus enters the body, what treatments might be of benefit, and how society should take action to keep transmission low.

To dig into what scientists around campus are asking and learning, Penn Today spoke with several who have pivoted their research to focus on COVID-19. Their work, while in its early days, is in many cases already finding applications in the fight against this ferocious virus, and may well shape the next steps to defeat it.

Another respiratory infection, influenza, has been a focus of research led by Andrew Vaughan of the School of Veterinary Medicine. But Vaughan didnt hesitate to begin studies of the novel coronavirus once its eventual impact became apparent.

Its not a stretch for our lab, he says. All the projects in our lab focus on repair and regeneration of the lungs after injury. The majority of my studies are to some degree agnostic about what is causing the injury.

Earlier work by his group, for example, showed that a lung cell transplant could boost healing in mice affected by a severe bout with flu. Now, graduate students and research specialists in his labworking no more than two together at a time to maximize social distancingare conducting new experiments focused more specifically on the biology of SARS-CoV-2, alongside parallel efforts by Edward Morrissey from the Perelman School of Medicine (PSOM). Knowing that the Ace2 receptor on lung cells is the gateway for the virus into the human body, theyre genetically manipulating alveolar type-two lung cells, those that are particularly essential for continuing oxygen exchange deep in the lungs, to alter or block ACE2 gene expression to try to prevent viral entry.

These alveolar type-two cells seem to be particularly susceptible to injury in both influenza and perhaps even more so in COVID-19, says Vaughan. In a perfect world, you might be able to take these genetically edited type-two cells and use them as a cellular therapy. I dont know that this is going to happen in time to impact this pandemic, but even if the pathogen the next time around is slightly different, we may still be able to employ these types of regenerative responses to help the lung recover better from injury.

In a separate project, Vaughan is partnering with Penn Vets Montserrat Anguera to explore a curious feature of COVID-19 disease: the fact that more men than women become severely ill and die. A number of hypotheses have been put forward to explain the disparity, but the two labs are investigating one particular possibility.

Dr. Anguera had posted something on Twitter saying that the ACE2 gene happens to be on the X chromosome, meaning that women have two copies of it, says Vaughan. I immediately texted her and said, I think theres something to that.

Normally women inactivate one of their X chromosomes, but some genes can escape this inactivation. This means its possible women may have higher ACE2 expression than men. Somewhat counterintuitively, scientists have actually found that higher ACE2 levels actually reduce lung injury, even though ACE2 is also what the virus depends on to enter cells.

Hormone expression levels are, of course, another factor that may influence sex differences in disease. Together, Anguera and Vaughans groups are both studying ACE2 expression and exposing alveolar type-two cells to various hormones to see how expression of viral receptors, Ace2 and others, changes. Ultimately wed like to see if this changes susceptibility to infection, working with Susan Weiss and others, says Vaughan.

Individual differences in how people respond to infection may be influenced by their unique genomic sequences. Penn Integrates Knowledge Professor Sarah Tishkoff of PSOM and the School of Arts & Sciences, is probing the rich sources of genomic data her group already had in hand to look for patterns that could explain differences in disease susceptibility. As in Vaughan and Angueras work, ACE2 is a focus.

This gene is very important for general health, Tishkoff says. Women have two copies, men have one; it plays a role in regulating blood pressure; its in the kidneys; its in the gut. We want to understand the role that variation at this gene may play in risk for COVID-19, severity of disease in people with underlying health conditions, and differences in the prevalence of disease in men and women.

Using genomic data from 2,500 Africans collected for another project, Tishkoffs team is looking for patterns of genetic diversity. Early findings suggest that natural selection may have acted upon on version of the ACE2 gene, making it more common in some African populations with with high exposure to animal viruses.

Shes also collaborating with Anurag Vermaand Giorgio Sirugo of Penn Medicine to analyze genetic variation in samples from the Penn Medicine Biobank, looking in particular at people of African descent. Were seeing disturbing health disparities with COVID, with African Americans at higher risk for serious illness, says Tishkoff. This disparity mostlikelyhas to do with inequities in access to health care and socioeconomic factors, but were also looking to see if genomic variation may be playing a role.

Looking ahead, Tishkoff hopes to partner with Daniel Rader and others through the Center for Global Genomics and Health Equity to work with the West Philadelphia community. Wed like to do testing to understand the prevalence of infection and identify environmental and genetic risk factors for disease, she says.

The immune reaction to SARS-CoV-2 is a double-edged sword. The immune system is what eliminates the virus, says E. John Wherry of PSOM. The immune system is what we need to activate with a good vaccine. But also, especially in many respiratory infections, the immune system is what also causes damage. A healthy outcome means your immune system is striking a balance between killing off the virus and not doing so much damage that it kills you.

Wherry and PSOMs Michael Betts have embarked on a study to discern both the magnitude of patients immune responses as well as their flavor, that is, what components in the immune system are being activated by the coronavirus. Theyre doing so by working with clinicians at the Hospital of the University of Pennsylvania (HUP) and, soon, at Penn Presbyterian Medical Center, to collect blood samples from patients with severe and more mild infections, as well as patients who have recovered from illness, to profile their immune reactions.

Its one of the beautiful things about Penn. Everyone is working as a team, being selfless, being present, and bringing all their expertise to bear on this crisis. E. John Wherry, Perelman School of Medicine

We are observing a huge amount of heterogeneity across these patient samples, says Betts. But were also identifying some relatively unifying characteristics, indicating there are mechanisms that everyone uniformly uses to fight off this infection.

This variety across patients strongly suggests that the treatments that work for one patient may not for another, Wherry and Betts note. For that reason, they are speaking daily with their colleagues on the front lines of COVID-19 care, relaying what theyre finding out in the lab to adjust and personalize care in the clinic.

Its one of the beautiful things about Penn, says Wherry. Everyone is working as a team, being selfless, being present, and bringing all their expertise to bear on this crisis.

Plenty of recent scientific attention has been paid to the role of the gut microbiome in health. But the medical schools Ronald Collman and Frederic Bushman have been devoting attention to how the community of bacteria, viruses, fungi, and parasites that dwell in the respiratory tract affect health and disease risk. They are now addressing that question in the context of COVID-19.

There are two reasons were interested in studying this, Collman says. First is that the microbiome can help set the tone for the immune response to infections, influencing whether a patient ends up with mild or severe disease. And second, the microbiome is where infectious agents that can cause infection can arise from. So if a patient dies of an eventual pneumonia, the pathogen that caused that pneumonia may have been part of that individuals respiratory tract microbiome.

Working with nurses at HUP to collect samples, Collman and Bushman are analyzing the microbiome of both the upper (nose and throat) and lower (lung) portions of the respiratory tract of COVID-19 patients. These samples are being used by other groups, such as those developing diagnostic tests, while Collman and Bushmans labs work to identify the types and quantities of organisms that compose the microbiome to find patterns in how they correlate with disease.

Were hoping that if we can find that the response to the virus is different in people with different upper respiratory tract microbiomes, then we could manipulate the microbiome, using particular antibiotics, for example, to make it more likely that patients would have a mild form of the disease.

Absent a vaccine, researchers are looking to existing drugssome already approved by the U.S. Food and Drug Administration for other maladiesto help patients recover once infected. Throughout his career, Ronald Harty of Penn Vet has worked to develop antivirals for other infections, such as Ebola, Marburg, and Lassa Fever.

Our antivirals are sometime referred to as host-oriented inhibitors because theyre designed to target the interaction between host and viral proteins, says Harty. Though many of the biological details of how SARS-CoV-2 interacts with the human body are distinct from the other diseases Harty has studied, his group noticed a similarity: A sequence hes targeted in other virusesa motif called PPxYis also present in the spike protein of SARS-CoV-2, which the coronavirus uses to enter cells.

This caught our eye, says Harty, and piqued our interest in the very intriguing possibility that this PPxY motif could play a role in the severity of this particular virus.

Harty is testing antivirals he has helped identify that block the replication of Ebola, Marburg, and other viruses to see if they make a dent on the activity of SARS-CoV-2. Those experiments will be done in collaboration with colleagues whose labs can work in BSL-III or -IV laboratories, such as Penns Weiss.

Also of interest is the speculation that the coronavirus might disrupt cell-cell junctions in the human body, making them more permeable for virus spread. Hartys lab will be examining the potential interactions between the viral structural proteins and human proteins responsible for maintaining these cellular barriers.

Another faculty member is assessing whether a drug developed for a very different conditionin this case, pulmonary arterial hypertension (PAH)could serve coronavirus patients. Henry Daniell of the School of Dental Medicine recently shared news that a drug grown in a plant-based platform to boost levels of ACE2 and its protein product, angiotensin (1-7), was progressing to the clinic to treat PAH. Daniell is now working with Kenneth Margulies from Penn Medicine to explore whether this novel oral therapy can improve the clinical course of patients with symptomatic COVID-19 infection.

Reduced ACE2 expression has been linked to acute respiratory distress, severe lung injury, multi-organ failure and death, especially in older patients. The earlier preclinical studies in PAH animal models showed that orally delivered ACE2 made in plant cells accumulated ten times higher in the lungs than in the blood and safely treated PAH. Now, new clinical studies have been developed to explore whether oral supplementation of ACE2 and angiotensin-1-7 can help mitigate complications of COVID-19 disease. The fact that freeze-dried plant cells can be stored at room temperature for as long as a year and can be taken at home by COVID-19 patients make this novel approach an attractive potential option.

This trial has been given a high priority by the Penn Clinical Trial Working Group, says Daniell. Im pleased that this looks to be on the cusp of moving forward to help the growing number of COVID-19 patients.

As the coronavirus began to spread in the United States, biologist Joshua Plotkin of the School of Arts & Sciences began to raise alarms about Philadelphias St. Patricks Day parade, which had been scheduled to be held March 15, potentially drawing thousands to downtown streets. He had good reason to be concerned: His studies of the 1918 flu pandemic had explored disease incidence and spread, and it was hard to avoid noticing the role of the Liberty Loan parade down Broad Street in triggering a rampant spread of flu a century ago.

Now, with work conducted with two graduate students from Princeton University, Dylan Morris and Fernando Rossine, along with Princeton faculty member Simon Levin, Plotkin has mathematically sound advice for policymakers hoping to effectively stem the spread of a pandemic. In a preprint on arXiv.org, they share optimal, near-optimal, and robust strategies for how to time interventions such as social distancing.

This boils down to knowing what is the best way, of all the infinite possibilities, to intervene using public health measures, says Plotkin. Thats a problem we can solve with math, my colleagues Dylan and Fernando realized.

Their analysis makes the realistic assumption that policymakers can only enforce social distancing for a limited amount of time, and aims to minimize the peak incidence of disease. The optimal strategy, they found, is to start by introducing moderate social distancing measures to keep the incidence rate the same for a period of time. This would mean that every person with COVID-19 would infect one additional person. Then the intervention should switch over to a full suppressionthe strongest possible quarantinefor the rest of the period. At the end of that period, all restrictions would be lifted.

This works because you dont want to fully suppress disease spread right off the bat, says Plotkin, because then at the end, after you remove restrictions, there will be a second peak that is just as large as the first. By employing a moderate suppression at the beginning, youre building up a population of people who are going to recover and become immune, without letting the epidemic get out of control.

Unsurprisingly, timing is key. Attempting the optimal intervention would be disastrous, in practice, because of inevitable errors in timing. Intervening too early is pretty bad, because you get a bigger second peak, he says. But intervening too late is even worse. The key lesson is that a robust intervention is more important than an optimal one.

Plotkin and his colleagues are hoping to share the findings widely, including with local decision makers, to help them navigate a likely second wave of COVID-19.

Montserrat Anguera is an associate professor of biomedical sciences at the University of Pennsylvania School of Veterinary Medicine.

Michael Betts is a professor of microbiology at the University of Pennsylvania Perelman School of Medicine.

Frederic Bushman is the William Maul Measey Professor in Microbiology at the University of Pennsylvania Perelman School of Medicine.

Ronald Collman is a professor of Medicine at the University of Pennsylvania Perelman School of Medicine.

Henry Daniell is vice-chair and W.D. Miller Professor in the Department of Basic and Translational Sciences in the University of Pennsylvania School of Dental Medicine.

Ronald Harty is a professor of pathobiology and microbiology at the University of Pennsylvania School of Veterinary Medicine.

Kenneth Margulies is a professor of medicine and physiology and research and fellowship director of the Heart Failure and Transplant Program at the University of Pennsylvania Perelman School of Medicine.

Joshua Plotkin is the Walter H. and Leonore C. Annenberg Professor of the Natural Sciences in the Department of Biology at the University of Pennsylvania School of Arts & Sciences. He has secondary appointments in the Department of Mathematics and in the School of Engineering and Applied Sciences Department of Computer and Information Science.

Sarah Tishkoff is the David and Lyn Silfen University Professor with appointments in the Perelman School of Medicines Department of Genetics and the School of Arts and Sciences Department of Biology. A Penn Integrates Knowledge Professor, she is also director of the Penn Center for Global Genomics and Health Equity.

Andrew Vaughan is an assistant professor of biomedical sciences at the University of Pennsylvania School of Veterinary Medicine.

E. John Wherry is chair of the Department of Systems Pharmacology and Translational Therapeutics, director of the Institute for Immunology, and the Richard and Barbara Schiffrin Presidents Distinguished Professor at the University of Pennsylvania Perelman School of Medicine.

Homepage image: Researchers around the University are taking a variety of approaches to study the novel coronavirus (particles of which are shown in purple), informed by past expertise and newly formed collaborations. (Image: National Institutes of Health)

Excerpt from:
Coming together to solve the many scientific mysteries of COVID-19 - Penn: Office of University Communications

Industrial facilities, like this PCC, Panattoni property in Cartersville, GA, are heavily favored over other CRE assets, according to LightBoxs survey.

Its not the outright fear or negativity surrounding the COVID-19 outbreak that most concerns those in the commercial real estate (CRE) industry. Rather, its the uncertainty.

Thats according to a market confidence survey polling those in the broker, appraisal, lending, investing and environmental consulting/engineering sectors on how they have been impacted by COVID-19 and the resulting recession. LightBox, a real estate technology firm, conducted the poll from mid-April through the end of the month.

The survey indicates that the top three concerns for CRE professionals are the unknown duration of the pandemic, rising unemployment and the difficulty of accurately forecasting business activity.

There is no shortage of uncertainty about when sellers will be comfortable putting properties back on the selling block, when lenders will be less skittish about originations or when the impact of the pandemic on property values is clearer, says Dianne Crocker, principal analyst with LightBox. Ultimately, the effects on the commercial real estate market will vary by geography and asset class and will depend primarily on how quickly the health crisis is controlled and the duration of the economic shutdown.

Lenders, consultants, appraisers and others in the field fear the consequences of instability on their businesses long term, but current realities are similarly harrowing. Of the respondents, 74 percent have experienced a slowdown in transactions and prospective projects, while 46 percent report deal delays specifically related to inability to access sites for inspections. Only 11 percent of survey respondents indicated that they had experienced no negative impact to their productivity levels.

Among those surveyed, 30 percent have implemented a hiring freeze or have delayed hiring plans specifically because of the pandemic and its fallout, while 22 percent are actively downsizing.

Reluctance seems to be the plan for many. About one-third of respondents noted fewer new listings for properties and difficulty in arranging financing. Brokers noted that sellers are waiting to see how prices will be impacted by the shutdown.

Impediments to getting deals done included physical barriers: Nearly half of those surveyed said that a lack of access to sites for inspections (either because of site restrictions or health concerns on the part of assessors) had created delays. Similar difficulties (for 37.7 percent) arose as CRE professional were unable to obtain property data due to closures nationwide.

Nearly a quarter of those surveyed reported a rush to complete late-stage deals, particularly in cases where financing was already secured and due diligence completed.

In the near future, some brokers anticipate a surge in new properties on the market as uncertainty dies down and deals resume. This surge will be accompanied by an uptick in demand for reliable tenants as buyers consider an assets robustness and cash flow projections under a new set of market conditions, according to LightBoxs report.

The majority of respondents indicated that hope for a fast, V-shaped recovery was dead, with 53 percent indicating that they anticipated full recovery would not occur until August or later. Particular segments of those surveyed were more optimistic as whole: brokers, investors, consultants and engineers anticipated a faster and more complete return to normal than their significantly impacted peers in appraisals or lending.

Sarah Daniels

View original post here:
LightBox Survey: Longevity of Pandemic, Unemployment Are Top Concerns for CRE Professionals - REBusinessOnline

In Depth Market Research on Global Longevity and Anti-senescence Therapy Market with Industry Analysis, Trends, Competition and Forecast by 2026.

The global Longevity and Anti-senescence Therapy market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Researchs latest publication, titled global Longevity and Anti-senescence Therapy market, offers an insightful take on the drivers and restraints present in the market. It assesses the historical data pertaining to the global Longevity and Anti-senescence Therapy market and compares it to the current market trends to give the readers a detailed analysis of the trajectory of the market. A team subject-matter experts have provided the readers a qualitative and quantitative data about the market and the various elements associated with it.

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Longevity and Anti-senescence Therapy Market which would mention How the Covid-19 is Affecting the Longevity and Anti-senescence Therapy Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Longevity and Anti-senescence Therapy Players to Combat Covid-19 Impact.

Get the Sample of this Report with Detail TOC and List of Figures: https://www.qyresearch.com/sample-form/form/1493408/global-longevity-and-anti-senescence-therapy-market

The research report covers the trends that are currently implemented by the major manufacturers in the Longevity and Anti-senescence Therapy market including adoption of new technology, government investments on R&D, shifting in perspective towards sustainability, and others. Additionally, the researchers have also provided the figures necessary to understand the manufacturer and its contribution to both regional and global market:CohBar, TA Sciences, Unity Biotechnology, AgeX TherapeuticsInc, PowerVision Inc.,

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Longevity and Anti-senescence Therapy market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

Regions Covered in the Global Longevity and Anti-senescence Therapy Market:

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report Accurate market size and CAGR forecasts for the period 2019-2025 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Longevity and Anti-senescence Therapy market Exhaustive research on innovation and other trends of the global Longevity and Anti-senescence Therapy market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report segments the global Longevity and Anti-senescence Therapy market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritties of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also address political scenarios that are expected to impact the market in both small and big ways.The report on the global Longevity and Anti-senescence Therapy market examines changing regulatory scenario to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Ask for Customized Report as per Your Requirements: https://www.qyresearch.com/customize-request/form/1493408/global-longevity-and-anti-senescence-therapy-market

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Longevity and Anti-senescence Therapy market

Chapter 2: Evaluating the leading manufacturers of the global Longevity and Anti-senescence Therapy market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Longevity and Anti-senescence Therapy market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9 : To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

About Us:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View post:
Longevity and Anti-senescence Therapy Market Consumption Analysis, Investment Cost, Profits Data, Major Players, Trends and Forecast by 2026 | CohBar,...

Intel motherboards arent known for their longevity given the frequent socket changes for the companys different CPU generations. The latest rumours, however, suggest that Intel Alder Lake-S motherboards (which should succeed Rocket Lake-S, this in turn being a successor to the impending Comet Lake-S) will be compatible with up to three CPU generations.

The joke goes that each new Intel platform iteration introduces a new socket and the same architecture, and each new AMD platform iteration introduces a new architecture and the same socket. This isnt strictly true, of course in fact, recently announced Comet Lake-S motherboards should also support successiveRocket Lake-S CPUs with their LGA 1200 sockets, as Gigabyte announced (via VideoCardz) that its Z490 motherboards will support the next generation of CPUs. But the underlying point remains: Intel motherboards arent usually too forward compatible.

It now looks like this might be changing, however. A post on Chiphell (via VideoCardz) says that the LGA 1700 socket is rumoured to last up to 3 generations. Intels 10nm, big.LITTLE Alder Lake-S CPUs are rumoured to run on this socket, meaning (after Rocket Lake-S) we might have an Intel CPU generation not only boasting a new architecture, but also with some platform longevity to boot albeit with a hefty number of pins.

Now, I dont like to give too much credence to rumours, but this one would be fitting with what weve heard so far mainly that Intel Alder Lake-S could be switching things up a little both in its architecture and its fabrication process.

Theseprocessors might use a new core layout similar to ARMs big.LITTLE core structure a mix-match of big and little cores, surprisingly enough. As successors to Tiger Lake processors, they could very well utilise a 10nm process node for the smaller cores, moving away from the iterative 14nm fabrication process that has been used for so long.

This, combined with the fact that Intel already seems to be looking for some longevity with the LGA 1200 platform, means an Alder Lake-S platform with longevity doesnt seem too far fetched of a dream. And if these CPUs do end up bringing big architectural and process changes, it would make sense for LGA 1700 to stick around for a while. Heres hoping, anyway.

Visit link:
Future Intel motherboards might actually have longevity if these rumours are true - PCGamesN

In the USA: Perhaps this Mothers Day is more special. Its more than any important time to let the moms in your life know just how much each means to you. Of course, absolutely nothing can replace a loving hug or a compassionate touch. Or even knowing glances and those comfortable silenceshighly personal and togetherness moments that perhaps exemplify strength-of-relationship above all other. Even so, overt gestures of love and appreciation through gift-giving are always a welcome occasion. With this in mind, Ive curated a cross-section of gift ideas suited for nearly any kind of mom. These include an array of tech innovations to ease and enhance various facets of life to beauty. It also includes wellness, self-care, style, travel, and, of course, fine chocolate!

Help mom spoil herself on her special day, and every other day, with the RevAir Reverse Air Dryer. This ingenious invention replaces your blow dryer and in many cases, your flat iron too. Its a multi-functional hair tool that uses patented suction technology to dry hair in the natural direction of the cuticle (downward). It does so without damaging brushes or hot plates. This then locks out frizz and seals in shineand with minimal use of heat. So, mom can avoid those sweat-inducing blow-dry sessions. And its fast! RevAir dries, stretches, smooths, and straightens your hair in less than half the time of a blow dryer and flat iron. It reportedly performed 3.25 times faster than conventional blow-drying and straightening routines, according to third-party trials.

Unlike traditional devices, RevAir thrives when being used for final or stretch styles on the toughest hair types, even curly and coily hair. The system closes cuticles in their natural direction, reducing flyaways and increasing shine. Allure, Elle, and OK! Magazine have all agreed that its a Game-Changer, and mom surely will too.

The Orion and Radiance Photo Rejuvenation Red and Infrared LED Light Therapy Beauty Devices by Azure Medical Technologies will help mom put her best face forward. These high-tech tools use concentrated beams of red and infrared light to help remove and diminish skin blemishes, acne scars, and wrinkles.

Dermatologists and clinicians worldwide have used LED clinical devices for years to treat all types of facial wrinkles. But, with these, mom can experience the efficacy and convenience of this gentle and clinically proven light therapy technology in the privacy of her own home. Azures Radiance has a two times larger medical-grade lens than Azures Orion, a small version of the device. However, both devices are equally powerful and both have added features. These include proprietary beneficial microstructure diffusers and higher performing LED treatments.

The treatment is gentle and safe for in-home, clinical-level treatments and the sleek USFDA 510k cleared devices are cordless, rechargeable, portable, and simple to operate with a one-button operation. Both Radiance and Orion provide true super intense red through infrared light use, with four wavelengths of red and infrared, and very even beam patternsa MUST for quick and effective results and features the company reports as unmatched by any competitive device. Just a three-minute treatment, per three-inch-long area, five days a week for two months is recommended for optimal results.

Lets face it. All most moms want is help. And you can get her just that this Mothers Day with the Neato D7a premium and highly advanced robot vacuum that does the dirty work so mom (or anyone else in the family, perhaps including YOU) will not have to. This smart and powerful robot helper features top-of-the-line technology and is highly feature-rich.

This includes LaserSmart technology that allows it to intelligently navigate the home; zone cleaning that lets it clean specific areas on demand; no-go lines to keep the robot out of places it shouldnt be; turbo mode that boosts suction to pick up pet hair and tough debris; voice compatibility with Amazon Alexa, Google Assistant and Siri Shortcuts; and up to120 minutes of battery life.

Beyond all of those impressive considerations, what makes Neato particularly unique? First, the D-shape (which Neato first brought to the industry) was specifically designed to deep clean corners, unlike its round-shaped competitors. The extended battery life is also best-in-class, allowing for a bigger brush and dustbin. This makes it particularly perfect to give even large homes a more regular deep clean. Lastly, Neato is the only robot vacuum to use LiDAR technology for its laser mapping. So, Neato can scan and map the entire house, creating up to three multi-floor plans for the robot to follow. With lasers, Neato can even clean in the dark, getting those hard-to-reach places under furniture.

Cat ladies rejoice! While we all love our feline fur-babies, cleaning those messy and stinky litter box bins leaves much to be desired. However, Ive found a perfect solution, which offers a gift idea thatll keep on giving each and every day. Its the Litter-Robotthe highest-rated automatic, self-cleaning litter box on the market. It uses an innovative patented hands-free sifting system that is triggered automatically just minutes after your cat exits the unit, reducing the chance of a lingering unpleasant odor.

Beyond the luxury of not having to inhale all of those nasties, Litter-Robot also saves owners time by eliminating scooping. Plus it saves money by reducing overall litter usage up to 50%. This is because it only removes the clumps from the litter. Whats also super handy is that Litter-Robot 3 Connect pairs with the Connect smartphone app to help keep track of one or more units from anywhere at any time, which provides yet more freedom from litter box duties. It also allows for remote monitoring of waste drawer levels and usage history, providing insight into the cats overall health, as well as providing alerts for when the waste drawer is full. Being a good cat parent has never been this easy. Its better for mom and kitty as well. Oh, happy day!

As temperatures rise in May and into the summer months ahead, you can easily keep mom from getting too hot under the collar. In fact, you can readily keep her cool and collected with the powerful Honeywell Weatherproof Outdoor Portable Evaporative Cooler thats built to cool large outdoor spaces. This includes outdoor patios, porches, backyard decks, large common areas, studios, workshops, and more. The units triple-sided honeycomb and high-velocity fan deliver robust cooling to make any hot and humid outdoor space far more enjoyable.

This Honeywell cooler is definitely a welcome upgrade to outdoor living. This model is even equipped with an ice compartment, wide 14 metal fan blades, and a continuous water supply option since this unit uses water to cool hot air instead. New to evaporative air cooling? The sensation is like a lakeside breeze. Evaporative air coolers do not use heavy compressors or refrigerant gas to lower air temperatures, nor do they spray mist. Instead, they effectively reduce heat by evaporating water vapor into the air. They work most effectively in hot, dry climates. So keep momand all of her family and friendscool, comfortable, and confident in the summer months courtesy of the geniuses at Honeywell.

Help out your busy mom all year through by inviting Chef Emeril Lagasse into her kitchen! With this Power AirFryer 360 unit, mom can enjoy nearly effortless, one-touch cooking for almost any type of mealfrom healthier daytime snacks to decadent family roasts, all cooked in one appliance right on the countertop. The Emeril Lagasse Power Air Fryer 360 gives the versatility of an all-in-one and multi-cooker, with this particular unit using seamless airflow in combination with powerful, even heat.

Twelve one-touch pre-sets give endless cooking options: Air fry meals golden crisp using superheated hot air instead of the unhealthy oil of a deep fryer; dehydrate fresh fruit or jerky without added sugar or preservatives; air roast an entire 12-pound turkey; toast up to six slices of bread; slow cook stews; air bake decadent desserts and much moreall in one easy-to-use countertop appliance. Unlike ordinary units, the five all-over heating elements combine with 360-degree airflow cook meals to a perfect, even crisp on all sides, not just the top and bottom. The package even includes a cookbook full of Lagasse-created air fryer recipes developed exclusively for the Power Air Fryer 360. Plus, mom can do even more with the included accessory kit, which gives two additional Crisper Trays, one additional Pizza Rack, and a Rotisserie Stand.

Heres a style-savvy idea thatll help mom keep perfect time while looking fabulous all the while. Its unisex watches from KYBOE as featured on ShopLC! She can wear these snazzy timepieces anywhere. From the beach and gym to the office and those nights out on the town!

Highly versatile, these attention-getting accessories are great to pair with her dressier ensembles down to those casual outfits. These fashionable and functional KYBOE watches are constructed with sturdy stainless-steel cases, durable silicone bands, and sapphire-coated mineral glass. Each watch is operated with accurate Japanese quartz movement and is designed to keep ticking no matter what life throws at her.

Formed in 2007, Shop LC was originally known as The Jewelry Channel (TJC). In 2017, they decided to change the name to match what they offer: The opportunity to shop low cost (Shop LC means Shop Low Cost). Over the years, the Shop LC business model has evolved into an expansive shopping experience far beyond jewelry and gemstones, precious metals, and collectibles. Today, Shop LC features handbags and fashion accessories, beauty essentials, the latest in cooking and kitchen supplies, as well as luxurious, comfortable bedding and bath products for the whole family. So explore everything Shop LC has to offer this Mothers Day, youre sure to find the perfect fit for any type of mom.

Especially during these trying times, its more important than ever to let mom relax when she can. Life is busy and stressful enough, so heres a way to promote moms desire for fitness and mindfulnessall while staying stylish: Perfect Balance World clothing.

What makes this yoga brand unique is that its pieces have friction landmarks in the fabric. These landmarks help the yogi get a proper grip on the floor and, thus, better control over their own body. This enhanced grip allows yogis to keep their center of gravity resting in the ideal, balanced position while doing it with less strain and struggle. As a result, yogis achieve better, longer poses from the added control Perfect Balance World gear proffers.

One of my favorites from the collection is the Innovator Capri pants, featuring Landmark Grip that helps yogis to bend, stretch and invert beyond their traditional center of gravity. By building the balance into the Capris, users can hold those poses stronger, steadier, and longer.

Mom will love the intuitive fit that flatters the body, with a wide waistband that can be worn folded or unfolded. Made from a non-slip material, this polyester/spandex blend creates a soft, silky, and stretchable feel.

Another of my personal faves is DNA Leggings, which new students and seasoned yogis alike adore. The patented Landmark Grip design is again utilized and was built with the intention of keeping you accurately positioned during your practice so you can strike that pose with confidence!

Discover an activity that can not only help mom maintain her sanity in a time of upheaval, but also teach the entire family how to relax silently and focus (what more could mom want for her holiday, right?).

Buddha Board is a unique mindfulness tool that uses the act of creating as an outlet for emotions, thoughts, fears, and anxieties. By putting brush to slate, stress begins to be painted away. Simply paint the surface with water and the creation will come to life in bold design. Then, as the water slowly evaporates, the art will magically disappear leaving behind a clean slate and a clear mind, ready to create a whole new masterpiece all over again.

The simplicity of the products design creates a quiet space for adults and kids, alike, to explore their thoughts, reconnect with their feelings, and get grounded again. Buddha Board is inspired by the idea of living in the moment, wholly unplugged. It is also environmentally friendly as it only uses waterno ink, no paint, no chemicalsand it will last for years with proper care. Its a really soothing option and a great way for mom to enjoy simple acts of creative expression.

If youre anything like me, you travel heavy. But, were not alone, as throngs of women do. We overpack, making sure were fully prepared for any and every scenario during a trip. As such, it can take a village of suitcases to get to the final destination. But, luxury luggage purveyor Ebby Rane endeavors to change that with its Quartermaster option that any mom is sure to appreciate.

This suitcase is unique in many ways, including an interior boasting a patented packing design that helps better ensure full preparedness for those itinerary intensive jaunts. Efficiently designed for all carryalls to fit together, the Quartermaster boasts 12 pieces total to ensure theres a place for the essentials. Its also lightweight at just seven pounds; comes with a TSA-approved lock; has four 360-degree wheels that give the case an upright posture and a gentle glide, and a sturdy telescopic handle. Beyond functionality, the luggage also exudes elegance.

The Quartermaster has 10 luxurious gold-stamped Carryalls with hand-woven monkey knots and beautiful feminine ruffles; a branded dust cover for storage; and is trimmed in-and-out with vegetable-tanned fine quality leather. Also highly durable, its made of a 100 percent virgin polycarbonate shell that withstands those nasty bumps in the road; a leather top and side handles that are crafted and stitched to last; a water-resistant zipper; and an underside handle for effortless retrieval from overhead bins. A five-year guarantee ensures shell enjoy the Quartermaster for years to come.

Another fabulous option for those moms on-the-go is the Samsonite Mobile Solution Spinner Mobile Office. Like the name says, this is an office thats on the move! With a little bit of everything in one bag, the Spinner Mobile Office combines practicality, style, and functionality in a silhouette thats ideal for adapting from treks to the office, through that commute and wherever she needs to be overnight.

It features nylon twill fabric with vinyl trim and water-resistant coating, a retractable push-button handle, and front zippered pockets that are great for storing smaller items needing quick and easy access. Plus, an integrated USB Port provides power connectivity (battery not included). The Spinner Mobile Office even includes a patent-pending Wireless Charging Pocket that is designed to fit wireless batteries and phones for effortless charging on-the-run.

There is also an organized front pocket with accessory slip pockets therein, pen sleeves, card slots, and a larger slip pocket thats sized to fit most tablets up to 9.7-inches. A laptop compartment is made with a dedicated, padded section of the bag that fits most laptops up to 15.6-inches; including two accessory storage pockets.

There is also a dedicated compartment that maintains a separate packing area featuring cross straps to secure items and a divider to store additional travel or business items. The SmartSleeve technology fits over most upright luggage handles for easy mobility as well.

From the same company, and with the same ideals in mind, comes the Samsonite Encompass Womens Convertible Brief Backpack.

The model takes the guesswork out of organizing and packing so mom can get on with enjoying her day. Four wearable modes provide the flexibility and convenience needed for the fast-paced, modern commuter.

It has four-to-one convertibility: Backpackclip the strap to the secure D rings and adjust the fit to create the traditional backpack mode. Shoulderunclip the strap from backpack D rings and attach the adjustable shoulder strap to comfortably carry on the shoulder. Crossbodywhen packed full, adjust the shoulder strap to wear across the body for a more comfortable, secure, hands-free commuting mode. Toteremove the crossbody/shoulder strap and carry it by the tote handles on your arm or on your shoulder. It also has water-resistant body fabric that features a deep coating for protection against the elements.

A personal organization pocket is unique to this collection as the front includes pen sleeves and a slip pocket to hold all of her need-it-now business and personal essentials. The Brief Backpack also includes an RFID Data Vault, a protected pocket that will safeguard her otherwise vulnerable travel essentials from identity theft.

Does mom get nauseous when traveling via plane, train, boat, or automobile? Heres a sound, medicine-free solution to ease her pain.

Blisslets are fashionable wristbands that provide fast, drug-free, and effective nausea relief. How? Well, acupressure on the P6 (Nei-Kuan) point, located between the two central tendons below the wrist, has reportedly been used for thousands of years, by millions of people, as a natural remedy for nausea and vomiting due to motion, pregnancy and other causes.

While there are competing explanations for why exactly P6 acupressure has this soothing effect, multiple randomized scientific studies controlling for the placebo effect have indeed shown that it does offer relief. Blisslets deliver pressure to the P6 point on the wrists by means of a specially designed bead embedded in a comfortable elastic band.

For each arm, its as simple as positioning the pressure bead on the P6 acupressure point, which is located three finger-widths below your wrist creaseright between the two tendons on the underside. Blisslets come in two basic forms: elastics or as a combo with an elastic core that snaps into a decorative leather cover. In either case, the bracelets should feel snug but comfortable.

Blisslets come in pairs and mom can use them for as long as the condition causing nausea persists. Users may wear them for up to 48 continuous hours before taking a break. So help mom to experience greater comfort this year while traveling or amid other nausea-inducing incidences.

Theres perhaps no greater gift than the gift of health, and cautious moms out there will enjoy the peace-of-mind provided by the GermAwayUV Surface Sterilizer Wand. This travel-friendly handheld gadget uses natural UV-C light to sanitize and disinfect surfaces no matter where she may be: at home, a hotel room, a restaurant, a doctors waiting roomanywhere germs are sure to lurk (which is pretty much everywhere)!

This device uses the same advanced UV-C light technology that hospitals have been using to sterilize equipment for over 30 yearsbut now the technology is available to everyone at economical price points. This wand will eliminate bacteria, viruses, fungus, molds, and a host of other pathogens! Ultraviolet (UV-C) light technology is a really efficient and effective way to keep things germ free, and its certainly a better option than using harmful and messy chemicals to keep things sanitary.

Use on linens, bathroom fixtures, airline seats and trays, and nearly any other surface where germs live. It should also be mentioned that in addition to its germicidal usefulness, this UV wand also fights unwanted odors and allergens such as mold and dust mites. So, use it on those old gym sneakers, the kids grungy soccer bag, anything that stinks really. Its miniature size is convenient for daily life and for travel.

Should thisGermAwayWand be out-of-stock due to its efficacy and relatively economical price point, another handheld sterilizer solution worth considering isCureUV.coms18-watt UV-C Sterilizer,as its also a portable light-based tool that will disinfect and sterilize high traffic areas and other locations where bacteria and viruses congregate.

For moms who like to keep self-care in mind (or should), Royal Suttons Ultra Hydrating Body Souffl is a thoughtful gift idea. This indulgent product rejuvenates the skin from head-to-toe with luxurious moisturizing properties.

Infused with Thyme Extract and Vitamins A, C, and E, it helps the skin flourish and shine at its most natural peak. Its a great Mothers Day option because a little goes a long way. In fact, users only need a small amount to achieve great results.

I also love that its not too heavy and soaks into the skin quickly. In fact, thats one of the main differentiators of this item and others of its type on the market. Some are often overly greasy and do not absorb well.

The effects of this Ultra Hydrating Body Souffl will last all day. Its also an effective method for rejuvenating and conditioning a dry skin condition while helping retain moisture. This will leave the skin feeling softer, smoother, and more restored. The pleasant fragrance is also soft and not overpowering.

Heres a way to help enhance moms relaxation and soothe her mind this Mothers Day, courtesy of Yesterday Wellnesss Broad Spectrum Hemp Balm.

This light, gel-like balm formula is designed to promote a sense of calm while leaving skin feeling soft and refreshed. Its infused with lavender and eucalyptus oils, found to help with relaxation, sleeplessness, and anxiety.

Unlike oils, which need to be metabolized, the benefits of a balm take effect as soon as its absorbed into the skin. This particular U.S.-made product fully contains 1,000 milligrams of hemp extract per container and, according to the company, is independently lab-tested and verified to ensure potency, purity, and quality. Broad-spectrum CBD contains cannabidiol as well as over 100 other compounds found within the remarkable hemp plant, but no THC so theres no psychogenic effectunlike full-spectrum CBD.

All those incredible compounds work together synergistically to greatly enhance the potential health benefits of the plant; also known as the Entourage Effect. For its part, eucalyptus has been found to treat dry skin by boosting production of ceramides. Ceramides are a type of fatty acid responsible for retaining moisture. High in antioxidants, eucalyptus may also protect the body from free radicals and oxidative stress.

This balm also contains many anti-inflammatory compounds as well as eucalyptus. The company cites this as useful for decreasing anxiety and easing congestion. Meanwhile, when lavender is applied topically, it can reportedly help ease various conditions like menstrual cramps, eczema, sunburns, and acne. The scent is also believed to promote calmness and relaxation, as well as decrease stress, anxiety, and sleeplessness.

Another gift idea utilizing the benefits of CBD for particularly active moms, or those with frequent soreness, is Level Select. Designed as high-quality personal care CBD product, the company seeks to help people maintain a healthy and active lifestyle. This includes smaller everyday activities and physical exercise, to competitive sports and travel. It offers a comprehensive line of performance-based CBD Sports Creams, Roll-Ons and Oil Drops. These products are made with only the purest form of CBD oil, and without any THC. THC is the principal psychoactive constituent of cannabis.

Overall, CBD is a non-intoxicating cannabinoid found in cannabis. After tetrahydrocannabinol (THC), cannabidiol (CBD) is the second most abundant cannabinoid in the hemp plant. It is known to have many therapeutic benefits, including anti-inflammatory, analgesic, anti-anxiety, and seizure-suppressive properties. Level Select products are available in three levels of intensity. This allows consumers to choose the right option for their individual needs.

Level 1 is best used to relax muscles and treat everyday discomfort. On the other hand, Level 2 is higher in strength for a higher level of muscle soreness and relief. Level 3 provides maximum strength when its needed most. Level Select Sports Cream has a proprietary blend of Broad Spectrum and Nano CBD. With high-quality ingredients in a non-greasy formula, these products are soothing to the touch and are perfect for daily application. Level Select Sports Roll-ons also have a proprietary blend of Broad Spectrum and Nano CBD. Using high-quality ingredients in a massaging roller ball application, they help target the areas that need it most.

Finally, what Mothers Day would be complete without giving mom that quintessential box of chocolates? For a true delight, check out Dallmann Confectionsan Austrian-born, San Diego-based artisan chocolatier that recently launched an assortment of Chocolate Survival Gifts thatll keep mom longing for more. These exquisite, handmade confections are made with family recipes using high-quality European chocolate.

The gourmet gift boxes are designed with heartfelt messaging intended to offer comfort during these trying times. Chocolate is the way to many a womans hearts. As a result, company owner Isabella Knack has conceived three assorted survival kits. These are Sanity Saver, Chocolate and Chill and Chocolate Makes Everything Better.

Each comes with the option of nine pieces for $25, 16 pieces for $35, or 25 pieces for $45. Orders can be placed through the Dallmann Confections site and shipped within just two days. Some select items also sold on Amazon. But dont wait, because your perfect goodie giftable might not be there by the time you want to spoil mum! A Gift Box from Dallmann Fine Chocolates has the power to leave a lasting impression. Not just on her palate but in her heart, mind, and soul.

View original post here:
18 Ways to Impress Mom This Mother's Day - Longevity LIVE

Pacific University is proud to recognize its most dedicated employees with its annual faculty and staff awards.

The annual Faculty & Staff Honors & Awards Ceremony, scheduled for May 6, was canceled due to COVID-19 restrictions. The university, however, announced its awards to recognize employees virtually.

Today, we should be together, recognizing the exceptional work you have done at the Faculty & Staff Honors & Awards Ceremony, President Lesley Hallick said in an email to employees. But even though we are apart, I still want to take this opportunity to thank each of you and to especially call out the retirees and the exceptional individuals who have made notable impacts at Pacific this past year.

Pacific bestowed awards on 11 faculty and staff members, recognizing their contributions to teaching, student support, service and the university mission.

Among the awardees are Denise Goodwin of the College of Optometry, who was named Distinguished University Professor. The university also bestowed its Dedication to Students Award posthumously to Mike Charles, a College of Education professor who died earlier this year. See bios of all award winners here.

Additionally, the university recognized 16 long-time employees who retired, or are retiring, in 2019-2020 (meet the retirees) and honored those employees who have reached longevity milestones with Pacific (watch the award presentation).

The Boxer Spirit is, at its core, about people, Hallick said. You are what make the Pacific experience possible for our students, and you are what will carry us into the future.

Pacific University is the only comprehensive university in Washington County, Ore. Serving nearly 4,000 students in undergraduate, graduate and professional programs in the arts & sciences, business, education, health professions and optometry, Pacific is committed to discovery in a nurturing learning environment that pairs close, mentoring relationships with extraordinary educational experiences, research and service learning.

Pacific has moved more than 1,000 courses online this spring in response to the COVID-19 pandemic. As Oregon prepares to gradually reopen, the university is committed to offering its rigorous and personally meaningful academic programs this fall.

Read the rest here:
Pacific University Recognizes Faculty and Staff With Annual Awards and Honors - Pacific University

Ive been meaning to do this post for a while. It was originally planned for sometime in February, but I didnt get around to it before all the recruiting breakdowns I was doing. Then other things came up, and it kept getting pushed down the line. But here it is.

Its very rare a conference overturns half of its coaches in one single offseason. This was no ordinary offseason for the Mountain West, though. Some are familiar names, and others may be new. This post is giving each hire grades, broken up into different categories.

The first is the initial reaction, meaning perception when the coach was officially announced and had yet to do anything other than sign the contract, as some of the hires carried a bit more weight than others.

The next is their 2020 recruiting class. Yes, its a small sample size, and yes they all started at different times. But really, there isnt much else to go off of at this point.

Lastly, there will be a grade on longevity. Although it is a bit silly to think about how long these coaches will stay when they just got hired, ADs are certainly asking that question. Again, its hard to predict, will be subjective, and not the end-all, be-all when it comes to hiring a coach, but it does matter. Finding a coach who wont bolt after one winning season will help build or sustain the program.

Initial Reaction: A

Hiring Gonzales, the former Lobo player, and assistant coach was nothing short of a home run. The fact that they were able to hire him before the head coaching job at San Diego State opened up, and then he hired Rocky Long as his DC make stellar move continue to pay dividends.

Recruiting: B-

The fact that he is recruiting at all is a huge success, and one could argue this grade should be higher because of it. They turned in a pretty nice recruiting class all things considered, and it may be the first in a string of positively trending classes.

Longevity: A

Gonzales has strong ties to the New Mexico program and wouldnt figure to leave for just any job opening. He is as safe of a bet as any coach in the college football world.

Initial Reaction: A-

DeBoer was considered one of the top choices in the sudden Fresno State opening, having served as the offensive coordinator under Tedford before leaving for Indiana. Hes fairly young, is familiar with the program and players, and wanted the job. There is a lot to like here.

Recruiting: C-

DeBoer turned in a recruiting class similar to the ones Tedford produced. That is to say, average with some promise, but nothing that popped off the page. There will be some work to do in this area, or at least he will need to continue the emphasis on player development Tedford and his coaches were so good at.

Longevity: B

Its tough to say, but as a first-time coach, DeBoer will likely need to stay around to produce a few strong seasons before suitors begin to line up. Its unlikely he bolts before establishing himself.

Initial Reaction: A+

If Gonzales was a home run hire, then Arroyo was a grand slam. A top assistant at a top program, this was likely the best hire they could have made. It brought instant energy into the Rebel program, and they sorely needed it.

Recruiting: A

Arroryo got to work right away and landed one of the best recruiting classes in the entire conference. There is a lot of talent coming into the program, and its clear he is playing to his strength here.

Longevity: C+

Just a hunch, but it wouldnt be a surprise if this job is only a stepping stone for Arroyo. If he does well, he could easily cash in for a PAC12 job. However, its hard to be sure until the games are actually played, and the dominos begin to fall.

Initial Reaction: D+

This hire was puzzling when it was announced. The Rams were trading one .500 coach for another one? Addazio has head coaching experience, but he was just fired himself, and it appeared there were up and coming assistants with ties to the school available.

Recruiting: C+

Addazio went to work on the recruiting trail, going both local and nationwide for talent. He did alright with the time and challenges he had.

Longevity: B-

This one is actually a bit tougher to make a guess on. Does Addazio continue to be the coach he was before, and eventually Colorado State tries to upgrade again? Does he have success and try to get back into the P5? Or does he have success and settle in for the long haul, content with being a bigger fish in a smaller pond?

Initial Reaction: C+

Some may see this as a pretty good rehire, similar to Gary Andersen last year. Others may see these are a poor hire, since Hoke bolted after one good season the first time at SDSU and didnt do much at his other stops (which also sounds like Andersen). This grade splits the difference.

Recruiting: B-

San Diego State has turned in good but never great recruiting classes under Coach Long, and that basically seemed like what the Long/Hoke combo did this winter. Going forward, it seems like Hoke is focusing on recruiting earlier in the year, and it will be interesting to see if there is a shift in the type of players they recruit.

Longevity: C+

Similar to Addazio, maybe Hoke learns the grass isnt always greener, and its better to stay in a place where success is being had. Although, that success has been difficult to come by lately, so it seems like more of a toss-up.

Initial Reaction: C+

This hire was another one that was a bit questionable, but at least Graham has a pretty good track record as a coach and a very good track record as a person. He gets dinged a bit for not having ties to Hawaii, but he should be able to establish a culture there.

Recruiting: D+

Graham had next to no time to recruit and thus had to scrape things together in the last few weeks. I considered grading on a curve, but figured Id just tell it like it is, even if things were stacked against him. It will be interesting to see what happens in the class of 2021.

Longevity: B-

Who knows, really. Graham has made quite a few stops in his coaching career thus far. There are worse places to be at than the islands, but Hawaii doesnt pay much, and thats what caused local guy Rolovich to leave. Its probably safe to assume he stays a few seasons, which is a fairly long time in todays CFB landscape.

Again, its hard to honestly grade any of these hires until there are actual games being played. This is just going off of the perception of the hire and the small sample size of recruiting. Its guesswork, but there isnt much going on, so why not? Objectively, all of them have incomplete grades as it is too early to really judge. As for if these grades will hold up or be proven foolish, only time will tell.

These are one set of opinions. What do you think? Post in the comments below.

Read the original post:
Peak Perspective: Grading the New MWC Coaches - Mountain West Connection

When John Lynch and Kyle Shanahan took over the 49ers, one of their biggest offseason goals was to bring in a multi-talented running back fit for today's game.

They did so in signing Jerick McKinnon to a four-year deal in 2018. There's one problem, though: McKinnon has yet to play a regular-season down for San Francisco. An ACL injury and struggles with regaining comfort on the injured knee have kept the running back out of action for the last two seasons.

The former understudy to Adrian Peterson in Minnesota is turning to his old friend for a true test of where McKinnon stands at this point on his road to returning to football. He's heading to Houston to put himself through Peterson's legendary, marathon-like workouts.

"I feel like it's my last test to really see how it feels," McKinnon said, via The Athletic's Matt Barrows. "There's a lot of hard work going on down there. That's really where I'm going to amp it up as hard as I can and see where it goes."

Peterson's workouts are a significant source of his power, speed and longevity, with the latter prevailing most in recent years. It also set a standard for McKinnon, one he feels he must revisit now in order to fully grasp how prepared he is to return to football action.

"There were a lot of things back then that were tough," he said of his struggles with rehabilitation and a failed attempt to return to action in 2019. "I feel now that I'm getting back to where I was effortlessly."

McKinnon's absence has opened the door for other backs to shine. Matt Breida, Raheem Mostert and Jeff Wilson Jr. have all seen significant playing time in the last two seasons because the 49ers have had to find a way to replace what they lost with McKinnon's injury. Tevin Coleman would be the ideal complement to McKinnon (or vice versa) in a 2020 San Francisco backfield, which has been fine without McKinnon but could be even better with him.

The reason: McKinnon's lateral quickness and ability to change direction make him a very difficult target to cover in open space. Add that to an offense that's already masterful at times with Shanahan at the helm, and the reigning NFC champs only get stronger.

First, McKinnon will have to figure out how strong he is -- and he's going to get quite a test with the strong man nicknamed "All Day."

See the rest here:
McKinnon to test knee in workouts with AP - NFL.com

Ever since Apple announced the much-anticipated second coming of the iPhone SE, tech reviewers on both sides of the iOS vs. Android camp have been dumbfounded by just what a great value the smartphone seems to be. And while it is an impressive specimen in terms of fit, finish, and features, the hardware and appearance of the device are not what make it truly special. They're also not what makes the phone a legitimate threat not only to mid-range Android devices, but ostensibly to the entire Android ecosystem. No, that honor goes to something less obvious, less flashy, less sexy. The iPhone SE's real allure is all about the software/security updates and support. Period.

There had been rumors and speculation about the iPhone SE (2020) for years. Ever since the outsized popularity that the undersized 2016 handset generated, Apple faithful, as well as those still longing for quality, smaller phones with smaller price points, have been clamoring for a replacement to the original value iPhone.

It doesn't happen often in life, but in the iPhone SE (2020), fans basically got more of what they asked for.

Small iPhone fans were hopeful that any refresh to the 2016 SE would keep the original four-inch footprint, but bring a better processor, camera, and maybe some extras like wireless charging. This doesn't happen very often in life, but in the case of the SE, fans got most of (and in some cases, more of) what they wished for.

For a quick recap, the 2020 edition has a home button with Touch ID, a smaller and lighter form factor (though admittedly not as small as the original), the latest and greatest A13 processor, dual-SIM, portrait mode photos, IP67 water resistance, wireless charging, and the same affordable price from four years earlier.

For a thorough review of the iPhone SE (2020), head on over to iMore to read what my colleague Lory Gil had to say about the device.

Phone nerds (and not just Android fans) are quick to point out the iPhone SE's flaws and where it doesn't quite measure up to the mid-range Android devices it's positioned against from a price perspective. It's true, the design of the SE does look a little dated (if iconic) compared to something like the Pixel 3a, Nokia 7.2, or even Moto G Stylus. It has a much lower resolution screen than phones at that price point and cheaper, and it doesn't have a high megapixel camera, a 3.5mm headphone jack, a USB-C charging port, super-fast wired or wireless charging, or the large capacity batteries of many of its competitors.

The thing that got most tech folks excited about the iPhone SE was not the nostalgic form factor or stunningly fair price from Apple. Rather, it was the fact that Apple put its latest high-powered A13 processor into the device. The A13 is objectively better and more powerful at most tasks than anything that Qualcomm, Samsung, Huawei, or MediaTek have to offer the Android world, and it enables features and capabilities that most current mid-range Android phones can't match, (like enhanced image signal processing that makes the SE's iPhone 8-grade camera hardware perform on par with the iPhone 11 series).

The other thing that A13 enables is longevity. There's so much processing overhead in the chip that, at first glance, seems entirely unnecessary. Apple could have (and was expected to) easily gotten away with putting in an older A11 or A12 generation chip, and the SE still would have been a mid-range performance champ. But the secret is not about present-day performance it's about the long haul.

The A13 processor is overkill for now, but allows for long-term platform and security updates, among other improvements.

Apple's devices, and in particular, its iOS devices, are known to receive software and security updates for several years beyond what Android handsets get. iOS 13 is the current version of the software (iOS 13.4.1 at the time of writing, to be exact), and iPhones back to the 6S series and original SE, released in 2015 and 2016 respectively, are both capable of running it. And even though Apple forked iPadOS from iOS in 2019, iPads back to the Air 2 can run iPadOS based on iOS 13 (that's a 2012 device!).

This strategy helps Apple to not alienate fans who are slower to adapt to change, allows them to attract price-conscious smartphone shoppers and potential platform switchers, and allows them to follow their stated environmental focus by keeping phones in use and out of landfills for longer.

Older iOS devices can indeed run current software and get near-immediate, over the air (OTA) updates without waiting for carriers or other OEMs to make any changes, but that doesn't mean that they'll be able to take advantage of new platform features that rely on new hardware like advanced camera features and futuristic AR capabilities. But that's not the point. If flashy new hardware features are what you really want, then you're likely to fork over the additional cash for a more premium device like the Samsung Galaxy S20 series, OnePlus 8 Pro, or iPhone 11 Pro series.

Thanks to that beefy A13 and Apple's commitment and ability to push platform and security updates, by the time 2024 or 2025 rolls around and we're here reviewing what Moto G15 or Samsung A56 phone to get, the SE will probably still be ticking along just fine on iOS 17 or 18. Not too bad for $400 spread out over four or five years!

For a more thorough discussion of this topic, I encourage you to listen to the latest Android Central podcast with guest Lory Gil of iMore.

I know that most people reading Android Central would scoff at the idea of switching to iOS in general, or the iPhone SE in particular, and that's not what I'm advocating for here at all. I simply wish that more Android OEMs would dedicate themselves to supporting the platform and their devices for longer than they currently do.

It's rare to find even premium flagships that promise more than one major platform update (outside of Google and OnePlus), and even rarer still among the mid-range and low-end segments of the market. I realize the adage "you get what you pay for" applies in tech as elsewhere, but I still wish more could be done here.

I know that Apple has several advantages that allow it to produce an affordable mid-ranger with long-term software support. It designs and manufactures its processors, software, and hardware, and has the benefit of only dealing with a handful of suppliers and economies of scale to push its prices down (when it wants to). But there are way more Android manufacturers and customers, and only a couple of chip manufacturers that matter, so you would think that some of them could find a way to compete here with the SE where it matters - longevity. Hopefully, some of them (ahem, Samsung and Google), are getting their rears into gear for 2021 and beyond.

Right now, if you don't want to spend a lot on a good smartphone but you do want the guarantee of multi-year platform and security updates, your choices are between the Google Pixel 3a, and the iPhone SE. Right now, both are available for under $400, and we're eagerly looking forward to a similarly priced, but better specced, Pixel 4a any day now!

Lots to like, especially the camera

The Pixel 3a isn't the newest budget phone on the market, but it still holds up as one of the best. Its OLED display is a joy to look at, performance is really good, and there's no topping its camera quality. Add that together with a clean build of Android 10, USB-C charging, and a headphone jack, and you're getting a lot for your money.

Read the original:
The iPhone SE's major win over cheap Android phones isn't hardware it's software updates - Android Central

Pete Alonso and David Wright arent exactly similar to one another.

Sure, theyre both right-handed, but one is retired and the others career is (hopefully) just getting started, theyre from different areas of the country, and they play different positions on the diamond. Last, but most certainly not least, Alonso has flashed the kind of prodigious power we never saw from Wright.

Despite all that, they are actually pretty similar to one another.

Each have represented the New York Mets in the best possible light given the period of time theyve been associated with the organization and had much anticipated MLB debuts. Wright is the last player New York named as the teams captain, and if things continue going in the current direction, Alonso could end up being next. Last, but most certainly not least (again), Wright is unequivocally the Mets best third baseman in team history, while Alonso has given himself a terrific head start with regard to etching his name in New Yorks all-time record books.

When thinking about these two guys and how they could continue being connected to one another heading into the future, I got to thinking about one final similarity that one has achieved and one has a chance to achieve: continuity at their respective positions.

With regard to total games played at third base, Wright easily has the top spot on the leaderboard, suiting up to man the hot corner 1,586 times. The man in second place Howard Johnson would have to come out of retirement and more than double his current career games played at third (835) for the Mets to catch the Captain. Theres approximately as much space between Wright and Johnson as there is between Johnson and Joe Torre, who sits at 28th place with 87 games played.

As he typically did during the healthy portion of his playing career, Wright also brought the noise on a yearly basis. The Mets had a handful of good third basemen between 1962 and 2003, but there were only two occasions where someone led the team in games played at the position for more than three consecutive years: Hubie Brooks (1981-84) and Johnson (1987-91).

Then, of course, Wright took charge by leading in this category between 2004 and 2015, according to Ultimate Mets Database. That kind of longevity was something New York had obviously never had at this position before, and the top-tier production for the majority of that time was just icing on the cake.

Upon seeing this, I had to head over to first base in order to see whether Alonso could make a similar mark if he continued his current trajectory and was able to stick around in Flushing for the long haul. Hes got a ways to go before catching Ed Kranepool (1,302 career games at first base), but hes in good shape after just one year. There have been 164 different players to man first base as a Met, and Alonsos 153 games played from 2019 already has him at 19th all-time in franchise history.

Using the same parameters on a yearly basis, there have only been two Mets first basemen to lead the team in games played in more than three consecutive years: Kranepool (1964-69) and Keith Hernandez (1983-88). Kranepool does get some extra credit because he led the team in this category 10 times between 1964 and 1976.

Even though the 2020 season will feature a shortened schedule (if we get one), we can assume Alonso will reign supreme atop the games played leaderboard at first base for the second straight year, as long as hes healthy. That trend will almost undoubtedly continue through his pre-arbitration and arbitration years, which would already put him into the above exclusive club with Kranepool and Hernandez (again, assuming hes healthy). And if the Mets extend him beyond their initial team control, he could approach the territory Wright currently has on lock.

Alonsos National League Rookie of the Year campaign was certainly one to remember, and one the record books wont forget, either. He has a ways to go when it comes to having the kind of longevity thatll truly set him apart from the majority of players who have ever donned the orange and blue, but the future sure looks bright for the 25-year-old as he approaches his physical prime.

Continue reading here:
Another Potential Similarity Between Pete Alonso and David Wright - metsmerizedonline.com

DUBLIN--(BUSINESS WIRE)--The "COVID-19 Stem Cell Therapies Pipeline" report has been added to ResearchAndMarkets.com's offering.

Complementing the slew of vaccines in development are the upcoming stem cell therapies, aimed at boosting patients' immune systems and eliminating pathogens. The COVID-19 Stem Cell Therapies Pipeline report provides comprehensive data analysis of 22 organizations developing stem cell therapies for COVID-19 globally from the Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific region (APAC).

Some report features include:

The report covers stem cell therapy market with detailed review of their cell therapy research and development including the stages of production (pre-clinical, clinical and commercial). In addition, it pulls together insights from interviews and surveys with key opinion leaders. It seeks to holistically inform the community on the current status of COVID-19 stem cell therapy development and discover future opportunities for collaboration, technology transfer and co-development.

Key Topics Covered

Section 1

Section 2: COVID-19 Stem Cell Therapies Pipeline in the Americas

Section 3: COVID-19 Stem Cell Therapies Pipeline in EMEA

Section 4: COVID-19 Stem Cell Therapies Pipeline in APAC

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/kpp6tj

Read the original here:
COVID-19 Stem Cell Therapies Pipeline, 2020 Report - ResearchAndMarkets.com - Business Wire

"global Stem Cell Therapy market"

A new market study, titled Covid-19 Impact on Global Stem Cell Therapy Market Size, Status and Forecast 2020-2026 has been featured on WiseGuyReports.

The global Stem Cell Therapy market research offers a comprehensive overall market analysis focused on the latest findings. The introduction portion includes a brief overview of the industry, along with the product and service descriptions. This also includes the main applications for all end-user industries. The report also presents market prospects along with the forecast, with the study covering the period 2020-2026. The report includes an in-depth analysis of the major factors that could decide the market's trajectory in the coming years.

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

In the last several years, global stem cell therapy market developed fast at a average growth rate of 46.81%.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Stem Cell Therapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

The following players are covered in this report:

Osiris Therapeutics

NuVasive

Chiesi Pharmaceuticals

JCR Pharmaceutical

Pharmicell

Medi-post

Anterogen

Molmed

Takeda (TiGenix)

This report also analyses the impact of Coronavirus COVID-19 on the Stem Cell Therapy industry.

Regional and Country-level Analysis

The report offers an exhaustive geographical analysis of the global Stem Cell Therapy market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.

Stem Cell Therapy Breakdown Data by Type

Autologous

Allogeneic

Stem Cell Therapy Breakdown Data by Application

Musculoskeletal Disorder

Wounds & Injuries

Cornea

Cardiovascular Diseases

Others

Request Free Sample Report athttps://www.wiseguyreports.com/sample-request/5252275-covid-19-impact-on-global-stem-cell-therapy

Table of Contents

1 Report Overview

2 Global Growth Trends by Regions

3 Competition Landscape by Key Players

4 Breakdown Data by Type (2015-2026)

5 Stem Cell Therapy Breakdown Data by Application (2015-2026)

6 North America

7 Europe

8 China

9 Japan

10 Southeast Asia

11 India

12 Central & South America

13 Key Players Profiles

14 Analyst's Viewpoints/Conclusions

NOTE: Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Contact Us:

NORAH TRENT

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Media ContactCompany Name: Wiseguyreports.comContact Person: Norah TrentEmail: Send EmailPhone: +1 646 845 9349, +44 208 133 9349City: PuneState: MaharashtraCountry: IndiaWebsite: https://www.wiseguyreports.com

Continued here:
Impact of Covid-19 Outbreak on Global Stem Cell Therapy Market Future Opportunities and Forecast Analysis 2020-2026 - Press Release - Digital Journal

GlobalStem Cell TherapyMarket Report 2020, Forecast to 2025presents a historical overview of market size, revenue, share, forecast, and market drivers. The report features detailed insights and deep research on the globalStem Cell Therapymarket. The report studies various segments, as well as key opportunities in the market and influencing factors which will help businesses increase their footprints in the industry. A comprehensive analysis of the product scope and market risks has been given for the participants. The report shows the company profile of the major vendors along with their winning strategies to give business owners, stakeholders, and field marketing personal a competitive edge over others operating in the market.

Get Free Sample Report:https://www.magnifierresearch.com/report-detail/36202/request-sample

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

The Market Report Addresses:

The report provides historical and forecasts market data including demand, application details, price trends, and company shares of the leading manufacturers by geography, and estimation of the globalStem Cell Therapymarket size by volume and value. The growth estimation of the market is offered on the basis of calculation by various segmentation and past and current data. This market has been divided into types, applications, and regions. The report also covers the growth aspects of the market along with the restraining factors which are expected to impact the overall growth of the market in the estimated forecast period from 2020 to 2025.

The top manufacturers/suppliers which are currently operating in the globalStem Cell Therapymarket industry includes:Mesoblast, Regeneus, U.S. Stem Cell

By the product type, the market is primarily split into:Monotherapy, Combination Therapy

By the end-users/application, this report covers the following segments:Osteoarthritis (unspecified), Knee Osteoarthritis, Shoulder Osteoarthritis, Hip Osteoarthritis

Market Regions and Countries Level Analysis:

Regional analysis is a highly comprehensive section of this report. This segmentation sheds light on the sales of theStem Cell Therapyon regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market. Market segmented by region/country:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Access Full Report:https://www.magnifierresearch.com/report/global-stem-cell-therapy-market-report-2020-forecast-36202.html

Moreover, the report aims to deliver evaluation and essential information on the competitive landscape to meet the unique requirements of the companies and individuals operating in the market. The study recognizes the factors affecting the globalStem Cell Therapymarket growth such as drivers, restraints, opportunities, and trends. The report also recognizes emerging players with a potentially strong product portfolio and creates effective counter-strategies to gain competitive advantage. The report features reliable high-quality data and analysis which is suitable for supporting your internal and external presentations. The market research report will also help create regional and country strategies on the basis of local data and analysis.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@magnifierresearch.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@magnifierresearch.comWeb:www.magnifierresearch.com

Follow this link:
Global Stem Cell Therapy Market 2020 With COVID-19 Update by Development factors analysis, Competitive Strategies and Forecast to 2025 - Bandera...